Stock REDHILL BIOPHARMA LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases RedHill Biopharma Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0011223810

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
RedHill Biopharma Terminates License Agreement for Aemcolo
AQ
RedHill Biopharma : Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 - Form 6-K
PU
RedHill Biopharma : Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - Form 6-K
PU
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
PR
RedHill Biopharma : Announces First Patient Enrolled in U.S. Government- Supported COVID-19 Study - Form 6-K
PU
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
AQ
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
AQ
RedHill Biopharma : Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - Form 6-K
PU
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
PR
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis, New Publication
AQ
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
PR
Nasdaq Stocks Under $1 to Watch Now! VTAK, IVP, ONCO, AKTS, RDHL
AQ
RedHill Biopharma Announces $8 Million Registered Direct Offering
AQ
RedHill Announces New USPTO Patent Grant for Talicia for H. pylori Treatment Through 2042
AQ
RedHill Biopharma : and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola - Form 6-K
PU
RedHill Biopharma : Exercise of Existing Warrants Resulting in $4 Million Proceeds to the Company - Form 6-K
PU
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
PR
Small Cap Companies Spearheading Innovation in the Biopharma Healthcare Sector" INBS, RDHL, CDIO, VTAK, DNA
AQ
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
PR
RedHill Biopharma Announces the Transfer of its Listing to the Nasdaq Capital Market
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RDHL Stock
  4. Stock
  5. News RedHill Biopharma Ltd
  6. Press Releases